Abstract
A 30-item sell-report scale for the assessment of sexual functioning after treatment for gynecologic cancer was developed and pilot-tested with 30 patients in a department of radiotherapy in Dijon, France. So far this scalc appears to have satisfactory levels of reliability (split half, .80 inter-item consistency, .76). Future administrations are needed to establish its validity as well as its applicability in non-French populations. A shortened version of the scale was also developed and its levels of reliability and validity will be determined after it has been administered to a large number of Frcnch women with gynecologic cancer.